COMPANY OVERVIEW

Developing novel small molecule drugs targeting large areas of unmet medical need

---

LOCATION

Southampton, , UK

---

THERAPEUTIC AREAS

Urology

Women's Health

---

WEBSITE

https://www.vantia.com/

---

CAREER WEBSITE

None

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Oct 3, 2017

Vantia Therapeutics Announces Positive Results From its Phase III EQUINOC Study, a Pivotal Trial with Fedovapagon for the Treatment of Nocturia in Men with Benign Prostatic Hyperplasia

Jul 6, 2011

Vantia Therapeutics Raises £4 Million to Fund Clinical Development of its Lead Compounds

Feb 2, 2010

Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia USA - English USA - English

For More Press Releases

---